Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est

Benzinga Newsdesk www.benzinga.com Neutral 50.2%

Neg 0% Neu 50.2% Pos 0%

Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.98) analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$300.000 million to $270.000 million-$300.000 million vs $273.700 million estimate.